Sullivan & Cromwell’s City office has been busy this summer winning roles on two headline deals announced yesterday [8 September], working alongside Clifford Chance (CC) on both Cinven’s £2.3bn sale of pharmaceuticals group Amdipharm Mercury Company (AMCo) and advising Goldman Sachs on Mitsui Sumitomo’s £3.5bn Amlin purchase.
Teva’s $40bn generic-drug buy sees Latham & Watkins and Sullivan & Cromwell lead
Cross-border teams from Sullivan & Cromwell and Latham & Watkins have landed the lead roles on the $40bn takeover of Allergan’s generic-making business by Teva that has seen the Israeli pharmaceutical powerhouse also abandon its bid for Mylan.
Continue reading “Teva’s $40bn generic-drug buy sees Latham & Watkins and Sullivan & Cromwell lead”
Dealwatch: Herbert Smith Freehills leads on winning bid for £4.2bn Thames super-sewer project
Herbert Smith Freehills (HSF) have advised the consortium picked to deliver a £4.2bn super-sewer stretching 15 miles under London to prevent untreated sewage flowing into the Thames.
Dealwatch: Linklaters and CC act on New Look sale as South African billionaire Wiese continues UK high street buy-up
Less than 30 days after advising on the £1.3bn purchase of Virgin Active by South African billionaire Christo Wiese’s private equity vehicle Brait, Linklaters‘ rising star Alex Woodward has led on Brait’s £780m deal for a 90% stake in clothing retailer New Look.
Dealwatch: Magic Circle lead on £5.2bn Aviva takeover of Friends Life
In one of the biggest deals the UK insurance sector has seen in years, Aviva‘s acquisition of Friends Life for £5.2bn has also gifted Magic Circle trio Linklaters, Allen & Overy and Clifford Chance with leading advisory roles.
Continue reading “Dealwatch: Magic Circle lead on £5.2bn Aviva takeover of Friends Life”